CDSCO Cracks Down on Promotion of Weight-Loss Medications, Boosts Regulatory Scrutiny

Central Drugs Standard Control Organisation (CDSCO) Issues Advisory on Pharmaceutical Marketing Practices

On March 11, the CDSCO issued an advisory warning pharmaceutical companies against indirect and surrogate promotion of prescription medicines for weight loss and metabolic disorders. The regulator stated that companies using disease-awareness campaigns, digital outreach, and influencer-driven content to create brand recall for prescription-only therapies are violating the law.

The advisory highlights the growing issue of GLP-1 usage in India, where metabolic disease burden is mounting. CDSCO aims to establish clearer boundaries around ethical promotion and prevent consumer manipulation, particularly among vulnerable populations. The regulator emphasized that any advertisement, direct or indirect, promoting prescription medicines to the general public, inflating efficacy claims, or implying guaranteed weight loss outcomes will be deemed misleading and may trigger regulatory action.

CDSCO stressed that obesity is a chronic condition requiring comprehensive management and that pharmacologic therapy should not be portrayed as a shortcut solution. The agency also warned against undermining national campaigns focused on diet, exercise, and preventive healthcare, which remain first-line interventions for weight management.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

The advisory scrutinizes campaigns disguised as "awareness initiatives" that generate product visibility or brand association for prescription molecules. Such tactics, including influencer endorsements, disease-specific microsites, and corporate storytelling, will be treated as surrogate advertising, a practice considered "seriously viewed and violative."

To strengthen transparency and accountability, CDSCO has asked pharma companies to:

• Prominently display authorized personnel details, office codes, and dedicated helpline numbers on product information sheets
• Establish a system for complaint logging and consumer query handling
• Submit Risk Management Plans (RMPs) to ensure continuous monitoring and risk-minimization for GLP-1 and other high-risk therapies

All manufacturers, importers, and marketing authorization holders have been instructed to align immediately with the advisory, which has also been forwarded to the Advertising Standards Council of India (ASCI) for oversight.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline